Decreased half life of cyclophosphamide in patients under continual treatment.

作者信息

D'Incalci M, Bolis G, Facchinetti T, Mangioni C, Morasca L, Morazzoni P, Salmona M

出版信息

Eur J Cancer (1965). 1979 Jan;15(1):7-10. doi: 10.1016/0014-2964(79)90198-1.

DOI:10.1016/0014-2964(79)90198-1

PMID:421718

Abstract

摘要

相似文献

Decreased half life of cyclophosphamide in patients under continual treatment.

Eur J Cancer (1965). 1979 Jan;15(1):7-10. doi: 10.1016/0014-2964(79)90198-1.

Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients.

Eur J Drug Metab Pharmacokinet. 1979;4(2):83-5. doi: 10.1007/BF03189405.

Metabolism of anticancer agents in man.

Ann N Y Acad Sci. 1971 Jul 6;179:432-41. doi: 10.1111/j.1749-6632.1971.tb46920.x.

Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.

Cancer Chemother Rep. 1974 Sep-Oct;58(5 Pt 1):697-703.

Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Br J Clin Pharmacol. 1979 Sep;8(3):209-17. doi: 10.1111/j.1365-2125.1979.tb01004.x.

The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

Acta Pharmacol Toxicol (Copenh). 1974 Aug;35(2):98-106. doi: 10.1111/j.1600-0773.1974.tb00729.x.

Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

Cancer Chemother Pharmacol. 1983;10(3):192-3. doi: 10.1007/BF00255760.

Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer.

Gynecol Oncol. 1990 Feb;36(2):185-8. doi: 10.1016/0090-8258(90)90170-p.

Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma.

Arzneimittelforschung. 1988 Jun;38(6):839-42.

Clinical pharmacology of cyclophosphamide.

Cancer Res. 1973 Feb;33(2):226-33.

引用本文的文献

Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Clin Cancer Res. 2013 Jan 1;19(1):236-46. doi: 10.1158/1078-0432.CCR-12-1897. Epub 2012 Nov 8.

Clinical pharmacokinetics of cyclophosphamide.

Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003.

New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.

Pharm Res. 2000 Jun;17(6):645-52. doi: 10.1023/a:1007561727948.

Metabolism and pharmacokinetics of oxazaphosphorines.

Clin Pharmacokinet. 2000 Apr;38(4):291-304. doi: 10.2165/00003088-200038040-00001.

Ifosfamide clinical pharmacokinetics.

Clin Pharmacokinet. 1994 Jun;26(6):439-56. doi: 10.2165/00003088-199426060-00003.

The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.

Cancer Chemother Pharmacol. 1995;36(1):53-60. doi: 10.1007/BF00685732.

Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokinetics.

Cancer Chemother Pharmacol. 1981;6(2):117-20. doi: 10.1007/BF00262327.

Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

Cancer Chemother Pharmacol. 1983;10(3):192-3. doi: 10.1007/BF00255760.

Bioavailability of cyclophosphamide from oral formulations.

Eur J Clin Pharmacol. 1984;26(2):269-70. doi: 10.1007/BF00630298.

Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

Cancer Chemother Pharmacol. 1983;11(3):196-9. doi: 10.1007/BF00254204.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验